Yan Lin - Concepedia

Author

Yan Lin

University of Pittsburgh

Also Known As

Y Lin, Y. Lin, Yan LIN, Yan Lin

Publications

610

Citations

H-Index

Concepts

All Affiliations

University of Pittsburgh UPMC Hillman Cancer Center Penn State Milton S. Hershey Medical Center National Cancer Institute University of California, Davis

About

Yan Lin is an author at University of Pittsburgh specializing in medicine, pharmacology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	272
2	Pathology	3	3	119
3	Cell Biology	1	1	23
4	Molecular Genetics	1	1	23
5	Obstetrics	1	1	62

Yan Lin

Publications

572

Citations

H-Index

Page 1

	Year	Citations
Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi Shawn Tahata, Shivendra V. Singh, Yan Lin, Cancer Prevention Research	2018	84
Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis Hussein A. Tawbi, Jan H. Beumer, Ahmad A. Tarhini, Annals of Oncology OncologyPhase I/ii StudyMelanomaPharmacologyMetastatic Melanoma	2012	67
Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt). Shannon Puhalla, Jan H. Beumer, Shalu Pahuja, Journal of Clinical Oncology Single-agent VeliparibBreast OncologyGynecologyPathologyPharmacotherapy	2014	62
Meiotically induced rec7 and rec8 genes of Schizosaccharomyces pombe. Yan Lin, Karin Larson, Russell Dorer, Genetics	1992	48
Lung Cancer Risk Prediction Using Common SNPs Located in GWAS-Identified Susceptibility Regions Joel L. Weissfeld, Yan Lin, Hui-Min Lin, Journal of Thoracic Oncology	2015	46
Correlative study on risk factors of depression among acute stroke patients. X-g Jiang, Yan Lin, Y-s Li PubMed	2014	44
Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies Leonard J. Appleman, Jan H. Beumer, Yixing Jiang, Cancer Chemotherapy and Pharmacology Advanced Solid MalignanciesMedicinePharmacologyPathologyAnti-cancer Agent	2019	37
Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome Jill M. Siegfried, Yan Lin, Brenda Diergaarde, Neoplasia	2015	31
A phase I study of veliparib (ABT-888) in combination with weekly carboplatin and paclitaxel in advanced solid malignancies and enriched for triple-negative breast cancer (TNBC). Shalu Pahuja, Jan H. Beumer, Leonard J. Appleman, Journal of Clinical Oncology Breast OncologyPharmacotherapyWeekly CarboplatinTumor BiologyPre-clinical Pharmacology	2015	29
Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program–Sponsored Single-Agent Phase I Studies Jan H. Beumer, Fei Ding, Hussein Tawbi, Journal of Clinical Oncology	2015	27

Page 1